Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre‐specified subgroup analysis of the randomized CASSINI study

Abstract Background Pancreatic cancer patients are at risk for venous thromboembolism (VTE); the value of thromboprophylaxis has not been definitively established. Methods This trial randomized cancer patients initiating a new regimen and at high risk for VTE (Khorana score ≥2) to rivaroxaban 10 mg...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Saroj Vadhan‐Raj, Mairéad G. McNamara, Marino Venerito, Hanno Riess, Eileen M. O'Reilly, Michael J. Overman, Xiao Zhou, Ujjwala Vijapurkar, Simrati Kaul, Peter Wildgoose, Alok A. Khorana
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2020-09-01
coleção:	Cancer Medicine
Assuntos:	major bleeding pancreatic cancer rivaroxaban thromboprophylaxis venous thromboembolism
Acesso em linha:	https://doi.org/10.1002/cam4.3269
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!